StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Jade Biosciences (JBIO)

Thu, 01 Oct 2026 06:57:23 -0400

H.C. Wainwright analyst Arthur He reiterated a Buy rating and $55.00 price target on Jade Biosciences (NASDAQ: JBIO).

The analyst commented: "On September 30, 2026, Jade Biosciences presented promising preclinical data on JADE301, its selective, half-life-extended anti-interferon beta (IFN-β) monoclonal antibody (mAb) for dermatomyositis (DM), at the 2026 European Academy of Dermatology and Venereology (EADV) Congress. The company also reviewed the data on a conference call with Rohit Aggarwal, M.D., M.S., Professor of Medicine at the University of Pittsburgh. Jade evaluated JADE301 side by side in the same assays against a dazukibart comparator generated from its publicly available sequence. JADE301 bound

Wedbush Reiterates Outperform Rating on Jade Biosciences (JBIO)

Thu, 01 Oct 2026 02:28:07 -0400

Wedbush analyst Laura Chico reiterated an Outperform rating and $47.00 price target on Jade Biosciences (NASDAQ: JBIO)

The analyst comments: “The company reported preliminary preclinical data for JADE301 at EADV and remains on track to kick off a Phase 1 healthy volunteer study in 4Q26. Preclinical JADE301 data demonstrates ~3x longer half-life vs. dazukibart (PFE, not covered). Additionally, the JADE301 SC and IV doses demonstrated similar time/concentration profiles. Phase 1 results will better inform on human dosing and safety. Bottom line, we see the initial data appearing supportive. No change to our JBIO estimates as we continue to leave JADE301 as

Stifel on Jade Biosciences (JBIO) Amid 1.5% Gain Today: 'We continue to like the stock here'

Wed, 30 Sep 2026 12:27:13 -0400

Stifel analyst Alex Thompson reiterated a Buy rating and $40.00 price target on Jade Biosciences (NASDAQ: JBIO).

The analyst comments "We're reiterating our Buy rating on JBIO following preclinical updates presented at EADV for recently-disclosed JADE301, a halflife extended anti-IFN-β mAb for Dermatomyositis. JADE301 is designed to improve upon Pfizer's IV anti-IFN-β dazukibart which has demonstrated Phase 2 proof-of-concept in DM. JADE301 has higher IFN-β affinity and potency vs dazukibart and a ~30-day IV half-life in NHPs (~3x dazukibart). Bioavailability support subcu administration. Jade plans to initiate a Ph1 in 4Q26 with an interim in 2H27 where the goal is matching

Form 8-K Jade Biosciences, Inc. For: Sep 30

Wed, 30 Sep 2026 07:13:00 -0400

si-local-file:///var/storage/secattach/20260930/27125187.html

Jade Biosciences shares preclinical data on JADE301 for dermatomyositis

Wed, 30 Sep 2026 07:00:50 -0400

Jade Biosciences (Nasdaq: JBIO) released preclinical data for JADE301, an investigational anti-interferon beta (IFN-β) monoclonal antibody in development for dermatomyositis, a rare autoimmune disease affecting approximately 50,000 adults in the U.S. The data were presented in an e-poster at the 2026 European Academy of Dermatology and Venereology Congress in Vienna, Austria.

According to the company, JADE301 demonstrated high-affinity binding to IFN-β with a KD of 11.3 pM, approximately 2.5-fold higher affinity than a dazukibart comparator, and showed no detectable binding to other interferon family proteins. In a human immune cell line, JADE301 inhibited downstream IFN-β signaling with an IC50 of 13

Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026

Wed, 30 Sep 2026 07:00:00 -0400

JADE301 is designed to build on a clinically validated IFN-β mechanism with a differentiated profile designed for infrequent subcutaneous dosing
JADE301 demonstrated high-affinity, selective IFN-β binding and greater functional potency than a dazukibart comparator in disease-relevant human cells
Following subcutaneous administration in non-human primates, JADE301 was effectively half-life extended with an approximately 25-day half-life and predictable distribution into muscle
JADE301 was well tolerated in non-human primates at all evaluated subcutaneous doses
Phase 1 healthy volunteer trial expected to begin in the fourth quarter of 2026; interim data anticipated in the second half of 2027
Company to host conference call and webcast today at

Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026

Wed, 30 Sep 2026 07:00:00 -0400

JADE301 is designed to build on a clinically validated IFN-β mechanism with a differentiated profile designed for infrequent subcutaneous dosing
JADE301 demonstrated high-affinity, selective IFN-β binding and greater functional potency than a dazukibart comparator in disease-relevant human cells
Following subcutaneous administration in non-human primates, JADE301 was effectively half-life extended with an approximately 25-day half-life and predictable distribution into muscle
JADE301 was well tolerated in non-human primates at all evaluated subcutaneous doses
Phase 1 healthy volunteer trial expected to begin in the fourth quarter of 2026; interim data anticipated in the second half of 2027
Company to host conference call and webcast today at

Form SCHEDULE 13G/A Jade Biosciences, Inc. Filed by: Venrock Healthcare Capital Partners III, L.P.

Fri, 14 Aug 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260814/26932237.html

Form SCHEDULE 13G/A Jade Biosciences, Inc. Filed by: Venrock Healthcare Capital Partners III, L.P.

Fri, 14 Aug 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260814/26932237.html

Form SCHEDULE 13G/A Jade Biosciences, Inc. Filed by: Bellevue Group AG

Fri, 14 Aug 2026 11:58:00 -0400

si-local-file:///var/storage/secattach/20260814/26927476.html

Form SCHEDULE 13G/A Jade Biosciences, Inc. Filed by: Bellevue Group AG

Fri, 14 Aug 2026 11:58:00 -0400

si-local-file:///var/storage/secattach/20260814/26927476.html

Jade Biosciences (JBIO) Misses Q2 EPS by 11c

Mon, 10 Aug 2026 16:15:26 -0400

Jade Biosciences (NASDAQ: JBIO) reported Q2 EPS of ($0.76), $0.11 worse than the analyst estimate of ($0.65).

For earnings history and earnings-related data on Jade Biosciences (JBIO) click here.

Jade Biosciences (JBIO) PT Raised to $47 at Wedbush

Mon, 10 Aug 2026 11:46:07 -0400

Wedbush analyst Laura Chico raised the price target on Jade Biosciences (NASDAQ: JBIO) to $47.00 (from $45.00) while maintaining a Outperform rating.

The analyst comments "Remain Outperform rated on JBIO, new $47 target. Most important in the 2Q26 update, all development timelines remain on track. Recent Otsuka (not covered) data provides important validation and read through to JADE101 in that it shows APRIL inhibition stabilizes kidney function in IgAN patients. With JADE101 showing greater potency and longer dosing intervals versus Voyxact, we like the potential for JADE101 to differentiate. No changes to our JADE101 estimates. Elsewhere in the pipeline, JBIO disclosed

Jade Biosciences (JBIO) PT Raised to $47 at Wedbush

Mon, 10 Aug 2026 11:46:07 -0400

Wedbush analyst Laura Chico raised the price target on Jade Biosciences (NASDAQ: JBIO) to $47.00 (from $45.00) while maintaining a Outperform rating.

Form 10-Q Jade Biosciences, Inc. For: Jun 30

Mon, 10 Aug 2026 07:22:00 -0400

si-local-file:///var/storage/secattach/20260810/26894304.html

Form 10-Q Jade Biosciences, Inc. For: Jun 30

Mon, 10 Aug 2026 07:22:00 -0400

si-local-file:///var/storage/secattach/20260810/26894304.html

Form 8-K Jade Biosciences, Inc. For: Aug 10

Mon, 10 Aug 2026 07:14:00 -0400

si-local-file:///var/storage/secattach/20260810/26894245.html

Form 8-K Jade Biosciences, Inc. For: Aug 10

Mon, 10 Aug 2026 07:14:00 -0400

si-local-file:///var/storage/secattach/20260810/26894245.html

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 07:00:00 -0400

Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy
Phase 2 JADE101 clinical trial in IgA nephropathy underway; interim data expected in 2027
Phase 3 JADE101 registrational trial in IgA nephropathy expected to begin in the first half of 2027
Began dosing participants with rheumatoid arthritis in Phase 1 trial of JADE201; interim data expected in 2027
JADE301, a potentially best-in-class, half-life–extended anti-IFN-β for dermatomyositis, now expected to initiate a Phase 1 healthy volunteer trial in the fourth quarter of 2026, with interim data anticipated in second half of

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 07:00:00 -0400

Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy

Phase 2 JADE101 clinical trial in IgA nephropathy underway; interim data expected in 2027

Phase 3 JADE101 registrational trial in IgA nephropathy expected to begin in the first half of 2027

Began dosing participants with rheumatoid arthritis in Phase 1 trial of JADE201; interim data expected in 2027

JADE301, a potentially best-in-class, half-life–extended anti-IFN-β for dermatomyositis, now expected to initiate a Phase 1 healthy volunteer trial in the fourth quarter of 2026, with interim data anticipated in second half of

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 07:00:00 -0400

Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy

Phase 2 JADE101 clinical trial in IgA nephropathy underway; interim data expected in 2027

Phase 3 JADE101 registrational trial in IgA nephropathy expected to begin in the first half of 2027

Began dosing participants with rheumatoid arthritis in Phase 1 trial of JADE201; interim data expected in 2027

JADE301, a potentially best-in-class, half-life–extended anti-IFN-β for dermatomyositis, now expected to initiate a Phase 1 healthy volunteer trial in the fourth quarter of 2026, with interim data anticipated in second half of

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 07:00:00 -0400

Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy

Phase 2 JADE101 clinical trial in IgA nephropathy underway; interim data expected in 2027

Phase 3 JADE101 registrational trial in IgA nephropathy expected to begin in the first half of 2027

Began dosing participants with rheumatoid arthritis in Phase 1 trial of JADE201; interim data expected in 2027

JADE301, a potentially best-in-class, half-life–extended anti-IFN-β for dermatomyositis, now expected to initiate a Phase 1 healthy volunteer trial in the fourth quarter of 2026, with interim data anticipated in second half of

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 07:00:00 -0400

Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy

Phase 2 JADE101 clinical trial in IgA nephropathy underway; interim data expected in 2027

Phase 3 JADE101 registrational trial in IgA nephropathy expected to begin in the first half of 2027

Began dosing participants with rheumatoid arthritis in Phase 1 trial of JADE201; interim data expected in 2027

JADE301, a potentially best-in-class, half-life–extended anti-IFN-β for dermatomyositis, now expected to initiate a Phase 1 healthy volunteer trial in the fourth quarter of 2026, with interim data anticipated in second half of

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 07:00:00 -0400

Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy

Phase 2 JADE101 clinical trial in IgA nephropathy underway; interim data expected in 2027

Phase 3 JADE101 registrational trial in IgA nephropathy expected to begin in the first half of 2027

Began dosing participants with rheumatoid arthritis in Phase 1 trial of JADE201; interim data expected in 2027

JADE301, a potentially best-in-class, half-life–extended anti-IFN-β for dermatomyositis, now expected to initiate a Phase 1 healthy volunteer trial in the fourth quarter of 2026, with interim data anticipated in second half of

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 07:00:00 -0400

Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy

Phase 2 JADE101 clinical trial in IgA nephropathy underway; interim data expected in 2027

Phase 3 JADE101 registrational trial in IgA nephropathy expected to begin in the first half of 2027

Began dosing participants with rheumatoid arthritis in Phase 1 trial of JADE201; interim data expected in 2027

JADE301, a potentially best-in-class, half-life–extended anti-IFN-β for dermatomyositis, now expected to initiate a Phase 1 healthy volunteer trial in the fourth quarter of 2026, with interim data anticipated in second half of